Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16130295 | 0.90 | PIK3CD (0.36) | PIK3CDLMNAKDM4E | |
| SCHEMBL25567925 | 0.87 | PIK3CD (0.45) | PIK3CDSLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL13303931 | 0.84 | PIK3CD (0.42) | PIK3CDSLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL4122365 | 0.82 | LMNA (0.43) | PIK3CDSIGMAR1LMNA | |
| SCHEMBL19699979 | 0.81 | SLC6A2 (0.36) | PIK3CDSLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL11932517 | 0.81 | PIK3CD (0.65) | PIK3CDSIGMAR1LMNA | |
| SCHEMBL16549293 | 0.80 | PIK3CD (0.64) | PIK3CDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25565751 | 0.80 | KDM4E (0.38) | PIK3CDSLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL29580790 | 0.79 | LMNA (0.41) | PIK3CDSIGMAR1LMNA | |
| SCHEMBL29580455 | 0.79 | LMNA (0.41) | PIK3CDSIGMAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-11767330-B2 | Citrate salt, pharmaceutical compositions, and methods of making and using the same | FOGHORN THERAPEUTICS INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-8101595-B2 | Antiviral indoles | Istituto di Ricerche di Biologia Molecolare P. Angletti SpA (IT) | 2012-01-24 | — | — | US | disclosed |
| US-20100076046-A1 | Antiviral Indoles | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076046-A1 | Antiviral Indoles | IDO1, ZC3HAV1, IFNAR1 | PIK3CD 4578/4885SLC6A2 3217/4885SLC6A4 1921/4885 |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | PIK3CD 1598/4885SLC6A2 3634/4885SLC6A4 4297/4885 |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | PIK3CD 1598/4885SLC6A2 3634/4885SLC6A4 4297/4885 |
| US-11767330-B2 | Citrate salt, pharmaceutical compositions, and methods of making and using the same | CS, SMARCC2, SMARCC1 | PIK3CD 37/4885SLC6A2 1213/4885SLC6A4 2439/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | PIK3CD 1598/4885SLC6A2 3634/4885SLC6A4 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.